You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股》藥捷安康(02617.HK)今起招股 一手入場費6,641.31元
生物製藥公司藥捷安康(02617.HK)公佈招股詳情,擬全球發售1,528.1萬股,香港公開發售佔一成,國際發售佔九成。每股招股價爲13.15元。每手500股,一手入場費6,641.31元。該股今日(13日)起招股,下週三(18日)中午截止,預期6月23日掛牌。聯席保薦人爲中信證券及華泰國際。 公司上市引入5名基石投資者,包括江北醫藥、康方生物(09926.HK)、華盛敦行、藥石地平線及科瓴安,共認購1.3億元公司股份。 此外,公司上市料淨集資約1.61億元,當中約90%用於爲核心產品Tinengotinib正在進行單藥治療CCA的多區域註冊III期臨牀試驗提供資金;約10%用於一般營運資金及一般公司用途。 Tinengotinib是一種獨特的多靶點激(酉每)抑制劑,主要靶向三個關鍵通路。Tinengotinib正進行兩項關鍵性╱註冊臨牀試驗,用於治療在過往接受FGFR抑制劑治療後疾病發生進展的膽管癌。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account